​Effective July 07, 2023, tamsulosin (Flomax^®), terazosin (Hytrin^®), doxazosin (Cardura^®) for the treatment of BPH and desvenlafaxine (Pristiq^®) and haloperidol (Haldol^®) for mental health treatment have been added to the ADAP formulary.

BPH is a non-cancerous enlargement of the prostate gland that commonly occurs as men age. Prostate gland enlargement squeezes the urethra and blocks the flow of urine out of the bladder. If untreated, BPH can lead to urinary tract infections, bladder stones, and kidney damage due to urine backflow to the kidney. As people with HIV successfully live longer on antiretroviral therapy (24.8 percent of people with HIV in California in 2020 were 60 years or older), BPH has become increasingly common. In addition, studies have suggested that HIV can cause inflammation in the prostate gland, which could contribute to the development of BPH. Fortunately, BPH can be treated, and treatment improves quality of life.

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor and is a common medication to treat major depressive disorder in people with HIV. Haloperidol is a first-generation antipsychotic medication. Although the ADAP formulary already includes a number of second-generation antipsychotic medication, the addition of haloperidol provides patient with more treatment options for the management of schizophrenia and other conditions.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of tamsulosin (Flomax^®), terazosin (Hytrin^®), doxazosin (Cardura^®), desvenlafaxine (Pristiq^®), and haloperidol (Haldol^®). If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,